transaminase

γ-Acetylenic GABA hydrochloride is a GABA transaminase inhibitor.

1. p-Hydroxybenzaldehyde (p-Oxybenzaldehyde) shows an inhibitory effect on the GABA transaminase to contribute to an antiepileptic and anticonvulsive activity, and its inhibitory activity was higher than that of valproic acid, a known anticonvulsant.

NNC 05-2090 hydrochloride is a betaine GABA transporter (BGT-1) inhibitor with an IC50 value of 10.6 μM.NNC 05-2090 hydrochloride can be used for the study of epilepsy and neurological disorders.

Bifendate (Bifendatatum) is commonly used to treat the transaminase elevation that caused by viral hepatitis and drug-induced liver injury.

Divalproex Sodium (Valproate semisodium) binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. It also is an HDAC inhibitor, Comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex may also work by suppressing repetitive neuronal firing through the inhibition of voltage-sensitive sodium channels.

L-DABA (L-2,4-Diaminobutyric acid) is an inhibitor of GABA transaminase with an IC50 greater than 500 μM.

Vigabatrin (Sabril), an analogue of gamma-aminobutyric acid, is an irreversible inhibitor of 4-aminobutyrate Transaminase responsible for the catabolism of γ-aminobutyric acid.

Vigabatrin Hydrochloride (γ-Vinyl-GABA hydrochloride) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA), which irreversibly inhibits the catabolism of GABA by GABA transaminase.

E17241 functions as an inducer of ABCA1 gene expression, effectively increasing its expression with an EC50 value of 280 nM. It also acts as an agonist for peroxisome proliferator-activated receptors (PPARs), inducing PPAR-mediated gene expression in HepG2 cells expressing PPARγ, PPARα, or PPARδ, with respective EC50 values of 290, 3,900, and 879 nM. In RAW 264.7 macrophage cells, E17241 enhances ACBA1 protein levels, although this effect is absent when siRNA targeting PKCζ mRNA is present. Treatment with E17241 (0.4, 2, or 10 µM) increases cholesterol efflux in RAW 264.7 cells. In an atherosclerosis model using ApoE- - mice administered with a dose of 25 mg kg, E17241 reduces levels of plasma cholesterol, alanine transaminase (ALT), aspartate transaminase (AST), and liver cholesterol and triglycerides, and also decreases the area of aortic lesions. Additionally, daily administration of E17241 (50 mg kg) lowers blood glucose levels and body weight in KKAy diabetic mice on a high-fat, high-glucose (HFHG) diet.

3HKT-IN-1 (Compound 17122279) is an inhibitor of Anopheles gambiae 3-hydroxykynurenine transaminase (3HKT) and is utilized in malaria research.

Gabaculine is an irreversible inhibitor of GABA transaminase (GABA-T; Ki: 2.9 μM). Gabaculine alters plastid development and differentially affects the abundance of plastid-encoded DPOR and nuclear-encoded GluTR.

MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model. |1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96(9), 2889-2897 (2011).|2. Haczeyni, F., Wang, H., Barn, V., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1(7), 663-674 (2017).

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)

Aspulvinone O is a fungal metabolite that has been found in P. variotti and has antioxidant and anticancer activities.1,2 It scavenges 2,2-diphenyl-1-picrylhydrazyl radicals in a cell-free assay (IC50 = 11.6 μM).1 Aspulvinone O inhibits aspartate transaminase 1 (GOT1; Kd = 3.32 μM) and is cytotoxic to PANC-1, AsPC-1, and SW1990 pancreatic cancer cells (IC50s = 20.54-26.8 μM).2 It reduces the oxygen consumption rate (OCR) and induces apoptosis in SW1990 cells. Aspulvinone O (2.5 and 5 mg/kg) reduces tumor growth in an SW1990 mouse xenograft model. |1. Zhang, P., Li, X.-M., Wang, J.-N., et al. New butenolide derivatives from the marine-derived fungus Paecilomyces variotii with DPPH radical scavenging activity. Phytochem. Lett. 11, 85-88 (2015).|2. Sun, W., Luan, S., Qi, C., et al. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. Cell Commun. Signal. 17(1), 111 (2019).

D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)

γ-Acetylenic GABA (4-Aminohex-5-ynoic acid) is a potent, irreversible inhibitor of GABA-transaminase, effectively raising the concentration of γ-Aminobutyric acid (GABA) in the brain of rats.

GABA-AT-IN-1 (Compound 6) inhibits γ-aminobutyric acid transaminase (GABA-AT) and crosses the blood-brain barrier.

BAY-069 is an inhibitor. BAY-069 inhibited branched-chain amino acid transaminase 1 (BCAT1) at IC50:31 nM and branched-chain amino acid transaminase 2 (BCAT2) at IC50:153 nM. BAY-069 is a novel (trifluoromethyl) pyrimidine dione chemical probe, which can be used for anticancer research.

Aspulvinone H is a natural inhibitor of glutamic oxaloacetate transaminase 1 (GOT1), suppressing glutamine metabolism, making PDAC cells sensitive to oxidative stress and inhibiting cell proliferation, exhibiting potent in vivo antitumor activity in an SW1990-cell-induced xenograft model.

1. Schisantherin B (Schizantherin-B) shows good effect in lowering the serum glutamic-pyruvic transaminase level of the patients suffering from chronic virus hepatitis.

Clofibric acid-d4 is intended for use as an internal standard for the quantification of clofibric acid by GC- or LC-MS. Clofibric acid is a peroxisome proliferator-activated receptor α (PPARα) agonist (EC50 = 50 µM in a transactivation assay) and the active metabolite of clofibrate. It is formed from clofibrate by tissue and serum esterases. Dietary administration of clofibric acid (0.067-0.22%) reduces serum cholesterol, phospholipid, and triglyceride levels in rats. It decreases glutamate oxaloacetate transaminase (GOT) levels and increases glutamate pyruvate transaminase (GPT) and lactate dehydrogenase (LDH) levels, markers of xenobiotic stress, in the plasma of carp (C. carpio) when administered in tank water at a concentration of 10 µg L. Clofibric acid has been found in wastewater effluent.

Aspartate aminotransferase (AST) is a transaminase enzyme, is often used in biochemical studies. Aspartate aminotransferase catalyzes aspartate and alpha-ketoglutarate converts to oxaloacetate and glutamate. Aspartate aminotransferase can be found in cerebrospinal fluid, exudates, and transudates [1] .

Gabazine free base is a specific antagonist of the GABA receptor. It does not affect GABA-transaminase or glutamate-decarboxylase activities.

Ac-Leu-Leu-Norleucinol (ALLN), a calpain inhibitor, is employed in the research of Acetaminophen-induced acute liver damage. It effectively reduces levels of glutamic-oxalacetic transaminase (ALT) and glutamic-pyruvic transaminase (AST) [1].